Skip to main content

Table 5 Adverse events of concurrent chemoradiotherapy in previously reported phase II/III randomized controlled trials

From: Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis

Study CRT regimen Leukopenia (%) Neutropenia (%) Thrombocytopenia (%) Anemia (%) Radiation pneumonitis (%) Radiation esophagitis (%)
All ≥3 All ≥3 All ≥3 All ≥3 All ≥3 All ≥3
RTOG 9410 [5] RT + VP NR 83.9 NR NR NR 9.3 NR 11.8 NR 12.5 NR 22.2
RT + EP NR 68.4 NR NR NR 16.0 NR 18.8 NR 16.9 NR 44.9
RTOG 0617 [41] LDR + PC 61.1 32.1 40.4 23.8 37.7 6.6 58.9 7.9 10.0 4.6 46.4 7.3
HDR + PC 57.0 30.8 46.7 26.2 41.1 7.5 58.9 8.0 12.1 1.0 54.2 15.0
LDR + PC + Cet 51.8 30.7 54.7 40.9 35.8 8.0 63.4 11.6 12.4 7.3 43.8 6.6
HDR + PC + Cet 54.0 37.0 59.0 46.9 44.0 16.0 51.0 6.0 17.0 6.0 54.0 19.0
PROCLAIM [42] RT + PP 36.7 22.6 42.8 24.4 55.0 40.3 40.3 8.8 17.0 1.8 48.1 15.5
RT + EP 40.8 30.1 54.8 44.5 85.0 29.0 45.6 13.6 10.7 2.6 50.7 20.6
CAMS [43] RT + EP
RT + PC
95.8
92.7
30.5
20.7
NR
NR
NR
NR
12.7
5.2
0
0
24.2
13.5
0
0
76.8
72.9
7.4
8.3
87.0
84.0
20.0
6.3
WJOG5008L [44] RT + SP 96.3 40.7 88.9 33.3 42.6 9.3 79.6 25.5 24.1 9.3 66.7 3.7
RT + VP 100 79.6 94.4 75.9 22.0 3.7 88.9 27.8 20.4 7.4 74.1 0.0
  1. CRT Chemoradiotherapy, RT Radiotherapy, LDR Low dose radiation, HDR High dose radiation, VP Vinblastine plus cisplatin, EP Etoposide plus cisplatin, PC Paclitaxel plus carboplatin, Cet Cetuximab, PP Pemetrexed plus cisplatin, SP S1 plus cisplatin, NR Not reported